Premium
Therapeutical significance of clopimozide in the treatment of chronic psychotic patients
Author(s) -
Cuyper H. J. A.,
Praag H. M.,
Mulder W. R. E. H.
Publication year - 1979
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1979.tb00256.x
Subject(s) - placebo , double blind , double blind study , open label , psychiatry , psychology , medicine , clinical trial , alternative medicine , pathology
This report, which concerns both an open and a double‐blind study, describes the activity profile and optimum daily dose of clopimozide (R 29 764) investigated in 40 chronic psychotic patients. The results of the open study indicated that clopimozide represents an equal, if not superior, choice versus the other neuroleptics which the patients had been receiving before the open study. Patients sought more contact with those surrounding them, were less preoccupied with their delusions and hallucinations, and showed a better adapted social behaviour. However, these results were not confirmed by the data from the double‐blind study ‐ showing that clopimozide was less superior to the placebo than expected on the basis of the open trial. Two hypotheses are advanced to explain this discrepancy: first, the difference in investigational method and second, possible over‐dosage of the drug at an average optimum daily dose of 13.95 mg.